Welcome to BONC Network
What has happened in Global business in the last week of September 2026 - Let's uncover it.
Do subscribe for regular overview by BONC Network editorial team on Global Business and financial market weekly.
BONC Network Newsletter - September 2026 Week 5
Market StudyBy BONC NETWORK · 30 Sep 2026
#boncnetwork#newsletter#globalbusiness#globalnews#financialmarket#financialnews#marketanalysis
Comments
No comments yet
Be the first to share your thoughts.
More from BONC NETWORK
Research
Top 10 Pharma Quarterly Revenue (Global & India)
1. Global Market Leadership (Q2 2026) Top 3 Global Players: Johnson & Johnson leads with $25.31B (+6.6% YoY), followed closely by Eli Lilly at $23.00B (+48.0% YoY) and AbbVie at $16.99B (+6.6% YoY). Massive Growth Drivers: Eli Lilly surged +48% YoY, driven by strong demand for obesity and diabetes treatments like Mounjaro and Zepbound. Eli Lilly also raised its 2026 revenue guidance to $85B–$87B. 2. Indian Pharma Landscape (Q1 FY2026–27) Top Performers: Sun Pharma leads the Indian market with ₹15,299.9 Cr (+10.5% YoY), followed by Aurobindo Pharma at ₹9,150.4 Cr (+16.3% YoY) and Lupin at ₹8,276.9 Cr (+32.0% YoY). Profitability Highlights: Sun Pharma: Net profit surged to ₹2,894.8 Cr (+27% YoY), with specialty medicine sales reaching $351M (21.9% of total revenue). Lupin: Recorded a +33.3% YoY sales surge with EBITDA up +42.8% (31.4% EBITDA margin). Zydus: Grew revenue by +22% YoY to ₹8,017 Cr, though net profit fell ~36% due to higher operational costs. 3. Focus Segment: Ophthalmic (Eye-Care) Market Global Leaders: Roche leads global ophthalmic revenue at $5.07B, followed by Bayer ($3.52B) and AbbVie ($2.11B). India Growth Outlook: The Indian ophthalmic drugs market is projected to expand from $253.1M in 2025 to $333M by 2030. Growth Drivers: Driven by higher eye disease prevalence, increased diagnosis/awareness, and rapid adoption of innovative therapies. 4. Key Strategic Growth Drivers Across the Industry Metabolic Therapies: High demand for obesity and diabetes care globally. Specialty & Oncology: Specialty medicines and oncology/immunology expansion are driving higher margins. Supply Chain & Infrastructure: Heavy investments in global manufacturing expansion (e.g., Lilly’s $4.5B Indiana expansion commitment). Domestic & Export Strength: Balanced growth across Indian domestic formulations and key international markets.
#globalpharma#boncnetwork#india
Market Study
BONC Network Newsletter - October Week 2 Business & Market Update
Hello BONC Network Users Welcome to the October Week 2 edition of the BONC Network Newsletter! Here is your curated snapshot of key global business developments, market trends, and economic updates shaping the landscape this month. 🌐 Top 5 Global Business Highlights Iran War & Hormuz Energy Shock Tensions persist after the rejection of proposals to reopen the Strait of Hormuz. With approximately one-fifth of global oil normally passing through the strait, the blockade has driven oil prices to $101.31/bbl (+55% YoY), continuing to fuel global inflation and currency pressures. US Federal Reserve Rate Hike The Fed raised its target rate by 25 bps to 3.75%–4.00%, citing elevated inflation. 16 out of 18 FOMC members anticipate at least one more hike this year, maintaining upward pressure on global borrowing costs. IMF Trims Global Growth Outlook Global growth is projected at 3.0% for 2026 and 3.4% for 2027. Global public debt is approaching 100% of GDP, limiting fiscal policy flexibility worldwide. US Tariff Policy Restructuring Following the striking down of IEEPA tariffs in February and the expiration of Section 122 surcharges in July, a new Section 301 duty (10%–12.5%) across ~60 economies has been implemented. Central Bank Tightening & Rising Bond Yields Rate increases across the US, UK, and Japan have pushed US 10-Year Treasury yields near two-decade highs (5.25%), driving capital movements from emerging markets. 📊 Global Market Snapshot & Economic Indicators S&P 500: 7,651.54 (+0.5% in Sept) Dow Jones: 50,906.05 (-4.3% in Sept) Nasdaq: 26,861.06 (+1.9% in Sept) Gold: $4,185/oz Indian Rupee: ~96.31 per USD (near record low) 🇮🇳 India Business Update Strong Economic Growth: Real GDP grew 7.8% in Q1 FY27 (above the 7% estimate), driven by Manufacturing (9.2%) and Services (10.0%). Inflation & PMI: CPI rose to 4.82% in August (with food inflation at 5.95%), while Manufacturing PMI stood at 52.8. Exports & IPOs: Merchandise exports surged 17% in April–July FY27, reaching a record $44.2B in July. The primary market remains active with potential IPO proceeds of ~₹25,000 Cr targeted for September. RBI Monetary Policy: The Repo Rate stands at 5.25%, with the market watching closely for upcoming MPC decisions. 💡 Sectoral Outlook for India Growth Opportunities: Capital Goods & Infrastructure, Textiles/Apparel (benefiting from trade agreements), Renewables, and Services. Watch Areas & Challenges: Auto and margin-sensitive sectors facing fuel/input cost pressures, and export sectors navigating foreign tariff adjustments. 📅 Key Upcoming Dates to Watch Oct 7: RBI MPC Decision Oct 13: US CPI & IMF Outlook Release Oct 28: Next Fed Meeting & Rate Decision Nov 30: India Q2 GDP Data Release Thank you for being a valued part of the BONC Network community.
#boncnetwork#newsletter#globalnews
